3B Blackbio DX Ltd

Q4 FY24Healthcare Services

3B Blackbio DX Q4 FY24 earnings call: Revenue & Margins

Q4 FY24 investor presentation: what the company reported on revenue, margins and projects.

Price₹1,406

Market cap₹1.1K Cr

P/E20.4

Updated24 Sept 2026

Read4 min read

Based on 3B Blackbio DX Ltd's Q4 FY24 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.

The short version

Q4 FY 2023-24 total revenue: INR 2,719.24 lakh vs. Quarterly EBITDA: INR 1,372.90 Lakh in Q4 FY 2023-24 vs.

From 3B Blackbio DX Ltd's Q4 FY24 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

Q4 FY 2023-24 total revenue: INR 2,719.24 lakh vs. INR 1,926.42 lakh in Q4 FY 2022-23 (approx. 41% increase).
Q4 FY 2023-24 molecular diagnostic kits export sales: INR 290.15 lakh vs. INR 188.33 lakh in Q4 FY 2022-23 (~54% increase).
Effective growth in Non-COVID Sales for Q4 FY 2023-24 approx. 20%, in line with expectations.
Diagnostics business (3B Standalone Non-COVID) Q4 Sales: INR 1,721.40 lakh vs. INR 1,433.41 lakh in Q4 FY 2022-23 (~20% growth).
Export business (non-COVID) increased by over 25% from previous fiscal, projecting 20-25% growth for next year.
TRUPCR Europe Limited, Manchester site expected 40-50% growth next fiscal year.

2 more points management made on revenue & sales performance

Profitability & Margins

Quarterly EBITDA: INR 1,372.90 Lakh in Q4 FY 2023-24 vs. INR 836.33 Lakh in Q4 FY 2022-23; an increase of approximately 64.3%.
Quarterly Profit After Tax (PAT): INR 879.03 Lakh in Q4 FY 2023-24 vs. INR 519.73 Lakh in Q4 FY 2022-23; an increase of approximately 69.1%.
Earnings Per Share (EPS): INR 10.26 in Q4 FY 2023-24 vs. INR 6.94 in Q4 FY 2022-23.

2 more points management made on profitability & margins

See what 3B Blackbio DX Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

The company is continuously investing in additional manufacturing and R&D facilities to support existing business verticals (Page 34).
Expansion efforts include enhancing operations at the UK subsidiary, TRUPCR® Europe Limited in Manchester, with a projected growth rate of 40%-50% next fiscal year (Page 24).
Funds will be deployed in a joint venture in Manchester, UK, dependent on need (Page 34).
No specific capex amount or exact timelines for new plants or projects are explicitly mentioned.

2 more points management made on capital expenditure plans

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

5x potential

1Health X Platform₹919 Cr

Rev 1Mar 1

2Chandan Healthca₹590 Cr

Rev 1Mar 3

3₹66.2K Cr

Rev 2Mar 1

4₹1.8K Cr

Rev 2Mar 2

5₹649 Cr

Rev 2Mar 2

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

The presentation does not explicitly mention any active fundraising through debt or equity.
There is no direct reference to a change in borrowings or net debt.
The Agrochemical division is stated to be operating with minimal debt, consistent with prior projections (Page 6).
The company is looking into eligibility criteria and formalities for National Stock Exchange (NSE) listing after amalgamation (Page 34), which may imply future capital market activities but no explicit equity raise is mentioned.

2 more points management made on fundraising & capital structure

See what 3B Blackbio DX Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The investor presentation does not explicitly mention or provide data on order book, order inflow, or pending orders. It focuses on: - Long-term contracts (Page 33) with over 20 contracts under a Reagent-Rental Model providing stable revenue, projecting 15%-20% business from these contracts. - Sales growth and export business expansion (Pages 16, 19) indicating increasing demand but without specific order inflow or pending orders data.

2 more points management made on order book & pipeline

3B Blackbio DX Ltd — Quarterly revenue & net profit

Revenue Net profit

Sep 2024

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Reported quarterly figures (₹ Cr). Latest: revenue ₹50 Cr, net profit ₹22 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What 3B Blackbio DX Ltd's management said in earlier quarters

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were 3B Blackbio DX Ltd Q4 FY24 results?

Q4 FY 2023-24 total revenue: INR 2,719.24 lakh vs. Quarterly EBITDA: INR 1,372.90 Lakh in Q4 FY 2023-24 vs.

What is 3B Blackbio DX Ltd share price analysis?

3B Blackbio DX Ltd currently shows a neutral. The stock trades at a P/E of 20.4 with a market cap of ₹1,132 Cr. Investors should review the full earnings analysis for detailed insights.

Is 3B Blackbio DX Ltd planning capital expenditure?

The company is continuously investing in additional manufacturing and R&D facilities to support existing business verticals (Page 34).

Keep 3B Blackbio DX Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.